Pharma

Day 1 at Lions Health: Use the data, stay persistent, and avoid being 'innovative'

Day 1 at Lions Health: Use the data, stay persistent, and avoid being 'innovative'

If there is one thing to take away from the opening day at the Cannes Lions International Festival of Creativity, it is this. Find the talks that inspire you, and then find the places with AC.

Lions Health: The 2017 pharma winners

Lions Health: The 2017 pharma winners

A public health campaign developed by McCann Health India for children in Afghanistan was the big winner in 2017.

U.S. campaigns make up one-third of Lions Health pharma shortlist

U.S. campaigns make up one-third of Lions Health pharma shortlist

By

In the Lions Health pharma shortlist, released Saturday morning, five branded campaign made it through the judging process for the branded prescription categories.

Five things for pharma marketers to know: Wednesday, June 14, 2017

Five things for pharma marketers to know: Wednesday, June 14, 2017

By

Sanofi to boost investment in biologics R&D; Sage's awareness campaign criticized; PatientsLikeMe poll finds 95% of patients want some costs of drugs covered

Healthcare brands turn to emotion, to better tell their stories

Healthcare brands turn to emotion, to better tell their stories

By

It's never been easy for pharmaceutical companies or healthcare brands to authentically engage with patients or with doctors.

Why Novartis' Shah-Mehta chose a career in pharma sales

Why Novartis' Shah-Mehta chose a career in pharma sales

By

The executive director of oncology marketing is fascinated by the resilience of the human body.

Five things for pharma marketers to know: Friday, June 2, 2017

Five things for pharma marketers to know: Friday, June 2, 2017

By

Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation

Keep Calm and Sell Drugs: Your New Daily Affirmation?

Keep Calm and Sell Drugs: Your New Daily Affirmation?

By

To be sure, anything borrowing from the well-known "Keep Calm" genre should not be construed as advice. The doctor is definitely not in.

Five things for pharma marketers to know: Tuesday, May 30, 2017

Five things for pharma marketers to know: Tuesday, May 30, 2017

By

Harvard Pilgrim signs two outcomes contracts with AstraZeneca; lobbyists fight over drug-pricing proposals; docs say no to adult ADHD screening test

Pricing pressure is the new new normal for drugmakers

Pricing pressure is the new new normal for drugmakers

By By

Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.

Gilead Sciences | 2017

By

Hepatitis C is so 2015 — at least, that's what Gilead Sciences CEO John Milligan is saying following his first year at the helm.

Pfizer | 2017

By

Is Pfizer finally in a position to close the Lipitor chapter, the one titled "how to bounce back from monumental loss"? All signs indicate yes.

Johnson & Johnson | 2017

By

After mulling over M&A options, Johnson & Johnson sprang into action in pursuit of Swiss biotech Actelion and initially received muted applause from investors.

Merck | 2017

By

The Kenilworth, New Jersey, company expects 2017 to produce the same worldwide sales scenario as last year. Yet despite the cautious outlook, stock prices are hovering higher than they were at this time in 2016.

Amgen | 2017

By

Biotech major Amgen is making good on a lofty promise to generate $1.5 billion in savings by 2018.

Teva Pharmaceutical Industries | 2017

By

The 2016 headliner for Teva Pharmaceutical Industries was its acquisition of Actavis Generics, which sent $33.43 billion in cash and about 100 million Teva shares to Allergan.

AbbVie | 2017

By

Any conversation about AbbVie has to begin with Humira, the best-selling drug in the world and the drugmaker's most important product.

Sanofi | 2017

By

Sanofi has been browsing in the acquisition aisle for some time now, even wheeling a few companies to the register only to leave empty-handed.

Roche | 2017

By

The FDA made patients, providers, and investors very happy when it approved Roche's Ocrevus in March.

Novartis | 2017

By

Following one of the most anticipated exclusivity losses of the decade, sales of Novartis cancer drug Gleevec slipped 28% in 2016 to $3.3 billion.

Eli Lilly | 2017

By

Eli Lilly has faced a rough patch. Last November, the company took a $150 million charge over its failed high-profile Alzheimer's disease drug solanezumab.

AstraZeneca | 2017

By

AstraZeneca brought its internal overhaul A game in 2016, leaving investors humming the tune of a much-needed turning point.

2017 Pharma Report: All the data in one place

2017 Pharma Report: All the data in one place

Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.

Alexion hires new chief commercial officer

Alexion hires new chief commercial officer

By

Brian Goff is expected to replace Carsten Thiel in June. The drugmaker said Tuesday that Thiel along with several other execs would be leaving the firm.

In Surprising Twist, Trust Rises for Healthcare Companies

In Surprising Twist, Trust Rises for Healthcare Companies

But will pharma and biotechnology firms be able to advance this year's positive momentum?

Study: One-third of docs trust pharma content on HCP sites

Study: One-third of docs trust pharma content on HCP sites

By

In general, physicians believe that information provided by pharma companies is difficult to find and lacking in science.

How Pharma Can Benefit from the Transformation of Pharmacy

How Pharma Can Benefit from the Transformation of Pharmacy

The pharmacist is being recognized as a key player on the healthcare stage and a main protagonist in the delivery of effective, outcomes-based care.

Value-based care requires innovators to challenge the status quo

Value-based care requires innovators to challenge the status quo

By

Execs stressed the importance of collaboration, consumer-mindedness.

Pharma faces its 'oh, shit' moment

Pharma faces its 'oh, shit' moment

By

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Five things for pharma marketers to know: Thursday, April 27, 2017

Five things for pharma marketers to know: Thursday, April 27, 2017

By

Novartis, Kaiser, and Qualcomm partner on heart-failure pilot; Novartis and GSK disclose DTC plans; cancer-treatment hype can be negative for patients